What is LOPJLB’s current signal on AKTX?

LOPJLB’s latest quantitative signal on Akari Therapeutics, Plc (AKTX) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is AKTX in?

Akari Therapeutics, Plc (AKTX) is currently classified in the CRISIS HMM market regime on LOPJLB.

Akari Therapeutics, Plc (AKTX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$8.77+7.87%Close

SELLCRISIS · day 8

RANGE

DATA 2026-10-09

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONEBEST

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $10M
Beta: 1.44
P/E (TTM): -0.01

Short % float: 2.67%
Days to cover: 1.0
SI change: +35.0%

1W: +0.57%
1M: -19.39%

vs SPY 1W: -0.59%
vs SPY 1M: -22.39%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The companyâs lead…

Employees: 6
Headquarters: US
Founded: 2014
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 1.1M
Float: 47.5%

akaritx.com ↗

Key executives

Abizer Gaslightwala — Chief Executive Officer, President & Director

Kameel D. Farag — Interim Chief Financial Officer

Satyajit Mitra — Executive Director & Head of Oncology

SEC filings

EDGAR · CIK 15411570 · AKTX

Analyst consensus

Buy

Bullish787.5%

Neutral112.5%

Bearish00.0%

L $19.50Avg $24.75H $30.00

Target$24.75+182.21%

Last$8.77

FAQ

What is LOPJLB’s current signal on AKTX?: LOPJLB’s latest quantitative signal on Akari Therapeutics, Plc (AKTX) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is AKTX in?: Akari Therapeutics, Plc (AKTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Akari Therapeutics, Plc (AKTX) do?: Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The companyâs lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to tre…

Key stats

Prediction markets

Company news

FAQ